Literature DB >> 9226783

Economic evaluation under managed competition: evidence from the U.K.

M Drummond1, J Cooke, T Walley.   

Abstract

Although economic evaluation in health care has a long-standing tradition in the United Kingdom, very little is known about its impact on decision making, particularly following the introduction of the internal market. Since managed competition appears to be growing in popularity worldwide, the U.K. is an interesting case study, as the reforms are well underway and there have been a number of efforts to conduct and disseminate economic evaluations. In this paper the potential for using economic evaluation in health care decision making in the U.K. is discussed. Then its actual impact is assessed in two ways. First, two case studies are discussed, on heart transplantation and the use of pharmaceuticals in the management of labour in pregnancy. Second, new data from a recent survey of potential users of economic evaluations are presented, with the emphasis on exploring the reasons for the impact, or lack of impact, of economic results. It is concluded that the NHS reforms increase the potential for the use of economic evaluation. However, there is a need to increase decision makers' awareness of economic studies and to help them interpret study methodology and results. Although worries about validity of economic studies are one of the major barriers to their use, other important barriers relate to the multiple objectives being pursued, of which increased efficiency is just one, and the difficulties of freeing resources from existing services in order to divert them to more cost-effective treatments and programmes.

Mesh:

Year:  1997        PMID: 9226783     DOI: 10.1016/s0277-9536(96)00398-x

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  21 in total

1.  Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET Project.

Authors:  J E Zwart-van Rijkom; H G Leufkens; J J Busschbach; A W Broekmans; F F Rutten
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

2.  Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees.

Authors:  A Anell; P Svarvar
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

Review 3.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 4.  Conflict of interest in industry-sponsored economic evaluations: real or imagined?

Authors:  M Barbieri; M F Drummond
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

5.  A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

6.  How can research organizations more effectively transfer research knowledge to decision makers?

Authors:  John N Lavis; Dave Robertson; Jennifer M Woodside; Christopher B McLeod; Julia Abelson
Journal:  Milbank Q       Date:  2003       Impact factor: 4.911

Review 7.  Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels.

Authors:  Marieke E van Velden; Johan L Severens; Annoesjka Novak
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Health professionals: how do they assess new medicines?

Authors:  Rebecca Cheng; Kirsty Cook; Sarah Dowman; Rebecca Lawn; Jemma Leary; Taryn Quinn; Kim Schroder; Nicola Smith; June Tordoff
Journal:  Pharm World Sci       Date:  2005-06

Review 9.  Pharmacoeconomic studies in Italy: a critical review of the literature.

Authors:  D Cornago; L Li Bassi; P De Compadri; L Garattini
Journal:  Eur J Health Econ       Date:  2006-12-21

Review 10.  Economic evaluation and decision making in the UK.

Authors:  Martin J Buxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.